SCHEMBL456668

SCHEMBL456668

N[C@@H](Cc1c[nH]c2cc(Cl)ccc12)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
KDM4E B2RXH2 2/20 0.66
LMNA P02545 2/20 0.66
MAPT P10636 2/20 0.66
TSHR P16473 2/20 0.66
BLM P54132 2/20 0.66
PMP22 Q01453 2/20 0.66
MEN1 O00255 2/20 0.66
MPO P05164 1/20 0.66
HIF1A Q16665 1/20 0.66
PTPRA P18433 1/20 0.65
CYP2C19 P33261 1/20 0.62
HTR2A P28223 3/20 0.61
ALDH1A1 P00352 1/20 0.61
CYP3A4 P08684 1/20 0.61
HTR1A P08908 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR2C P28335 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18029175 1.00 KMT2A (0.66) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL623336 1.00 KMT2A (0.66) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL29405769 1.00 KMT2A (0.66) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL128685 1.00 KMT2A (0.66) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL30381542 1.00 KMT2A (0.66) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL11602575 0.93 PTPRA (0.58) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL11604913 0.93 PTPRA (0.58) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL11602580 0.93 PTPRA (0.58) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL31642414 0.89 HTR2A (0.73) KMT2AKDM4ELMNAMAPTTSHR
SCHEMBL21309683 0.89 HTR2A (0.73) KMT2AKDM4ELMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 909 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US claimed
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US claimed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US claimed
US-20250177537-A1 AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF NATIONAL TAIWAN UNIVERSITY (TW) 2025-06-05 US claimed
US-20250154198-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2025-05-15 US claimed
CN-114689552-B Small molecule fluorescent sensor and application thereof 中国科学院天津工业生物技术研究所 2024-11-26 CN claimed
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 US claimed
CN-118354781-A Peptide inhibitors of interleukin-23 receptor 西兰制药公司 2024-07-16 CN claimed
US-20240228555-A9 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-07-11 US claimed
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP claimed
EP-1999259-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES California Institute of Technology (US) 2008-12-10 EP claimed
US-20080214439-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-09-04 US claimed
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-05-29 US claimed
US-20080096819-A1 Amino acid substituted molecules ALLOZYNE, INC. (US) 2008-04-24 US claimed
US-20080044854-A1 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2008-02-21 US claimed
WO-2007130453-A2 NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES ALLOZYNE, INC. (US) 2007-11-15 WO claimed
WO-2007103307-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-09-13 WO claimed
WO-2005097820-A1 PEPTIDES FOR INHIBITING MDM2 FUNCTION KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-10-20 WO claimed
EP-0421946-B1 3-indolepyruvic acid derivatives their method of production and therapeutic use POLIFARMA SPA (IT) 1996-11-20 EP claimed
US-4072691-A Process for the resolution of DL-6-chlorotryptophan TANABE SEIYAKU CO., LTD. (JA) 1978-02-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM KMT2A 1848/4885KDM4E 3819/4885LMNA 4762/4885
US-20080096819-A1 Amino acid substituted molecules BCAT2, DNPEP, PTMS KMT2A 839/4885KDM4E 2570/4885LMNA 3746/4885
US-20080214439-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS KMT2A 839/4885KDM4E 2570/4885LMNA 3746/4885
US-20080044854-A1 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES AARS1, TRMT1, NSUN3 KMT2A 915/4885KDM4E 1741/4885LMNA 3850/4885
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF GRPR, GIPR, GLP1R KMT2A 4091/4885KDM4E 4638/4885LMNA 785/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT KMT2A 2188/4885KDM4E 2649/4885LMNA 4184/4885
US-20250154198-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR IL23R, IL1RN, IL33 KMT2A 4359/4885KDM4E 4605/4885LMNA 4430/4885
US-20250177537-A1 AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF BTD, CALCR, CA6 KMT2A 1230/4885KDM4E 323/4885LMNA 1398/4885
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS KMT2A 839/4885KDM4E 2570/4885LMNA 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.